Ownership history in ALGERT GLOBAL LLC Β· 6 quarters on record
This page tracks every 13F SEC filing in which ALGERT GLOBAL LLC reported a position in KINIKSA PHARMACEUTICALS INTL (KNSA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π ALGERT GLOBAL LLC outperformed the S&P 500 by +39.2% annually on this KNSA position. Timing score: 75% (3/4 decisions correct). Average cost basis: $22.69. Maximum drawdown during holding period: β20.8%.
π₯ Exceptional β beat the S&P 500 by 39.2% per year on this position.
4 quarters analyzed
π― Smart timing β consistently buying dips and trimming near peaks.
3 of 4 add/trim decisions correct
Best entry: $19.78 (2024 Q4) Β· Worst: $27.67 (2025 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 1 trim. Bought during 1 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.02% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size